Cipla TQB2102 Licensing Deal Brings Sino Biopharm’s HER2 ADC to India and South Africa

Cipla has signed an exclusive licence for rolditamig deuderuxtecan (TQB2102), a late-stage HER2 biparatopic antibody-drug conjugate developed by China’s Sino Biopharmaceutical. The Cipla TQB2102 licensing deal, announced on 31 August 2026, gives Cipla the right to develop and sell the drug in India, South Africa and five other emerging markets, while Sino Biopharm’s subsidiary Chia Tai Tianqing (CTTQ) keeps manufacturing and global supply.

Cipla’s Indian disclosures did not publish financial terms. Hong Kong coverage of Sino Biopharm’s announcement put the deal at an upfront payment plus development, regulatory and sales milestones of up to USD 123 million, with double-digit royalties on net sales. The same reports describe TQB2102’s second regional out-licence and say the two partnerships have already generated about USD 30 million in upfront and milestone payments.

The asset and how it works

TQB2102 is a HER2 biparatopic antibody-drug conjugate developed by CTTQ as a China Class 1 innovative drug. Its dual-epitope antibody binds two non-overlapping HER2 domains, ECD II and ECD IV, which the originator says improves tumour selectivity and internalisation, including on HER2-low cells. The linker is enzyme-cleavable and the payload is a topoisomerase I inhibitor, the same mechanistic class as deruxtecan, with a drug-to-antibody ratio of about 5.8 to 6.0. The recommended Phase 2 doses are 6.0 mg/kg and 7.5 mg/kg every three weeks, given by intravenous infusion. No brand name has been assigned and the product is not approved in China, India, South Africa, the US or the EU.

Ad

Cipla TQB2102 licensing deal: the clinical evidence

In the first-in-human Phase 1 study (Ruan et al., Annals of Oncology 2026;37:1253-1265), 195 patients with advanced solid tumours were treated across 12 Chinese centres between March 2023 and February 2025, including 80 breast, 37 colorectal, 37 gastric or gastro-oesophageal, 22 lung and 19 other tumours.

Company-reported later-line data go further. In heavily pre-treated HER2-low disease the overall response rate was 53.4% (39 of 73 patients), rising to 58.3% (21 of 36) at the 7.5 mg/kg dose, with 44.4% responding among patients who had progressed on a prior antibody-drug conjugate. In HER2-positive advanced breast cancer the ORR was 58.8% (47 of 80), 67.4% at 6 mg/kg, with 63.3% responding after a prior ADC. A neoadjuvant Phase 2 in HER2-positive early breast cancer reported a pooled 73.1% total pathological complete response, 76.9% at the 6 mg/kg eight-cycle dose. An NSCLC readout at WCLC 2025 put the ORR at 62.7% in 51 evaluable patients.

These response rates are encouraging and the interstitial lung disease rate is low next to the label of trastuzumab deruxtecan. They are still single-arm or early comparative Chinese data, however. They do not prove superiority to Enhertu, and none have been generated in Indian or African populations.

The access case in India and South Africa

The commercial logic rests on HER2-low metastatic breast cancer, a large population that Enhertu (trastuzumab deruxtecan) validated globally but that remains poorly served on price and availability in much of South Asia and Africa. For Cipla the challenge is not scientific novelty. It is a set of market access and health economics questions: whether a China-origin ADC can be registered on a mix of Chinese Phase 3 data plus local bridging work, then reimbursed or tendered at a viable price in India (through NPPA pricing, state tenders and private insurance) and South Africa (private medical schemes and, later, public oncology). Cipla takes on local clinical development, regulatory filings and commercialisation; CTTQ keeps manufacturing, which leaves quality, capacity, export licences and geopolitics as single-source risks.

Achin Gupta, Managing Director and Global CEO of Cipla, framed the deal around access: “Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate. Through our partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access to this innovative treatment across licensed territories.” Eric Tse, CEO of SBP Group, kept it shorter: “Expanding global access to medicines developed by SBP Group is a central part of our strategy.”

The competitive set is crowded. Enhertu is the benchmark for efficacy, interstitial lung disease risk and price. T-DM1 (trastuzumab emtansine) is the comparator in TQB2102-III-02, an easier bar than Enhertu. Several other Chinese HER2 antibody-drug conjugates sit in Phase 2 and 3, and trastuzumab biosimilars plus chemotherapy remain the affordable standard in India and Africa. TQB2102’s pitch is comparable activity with a lower reported interstitial lung disease rate, but head-to-head data against trastuzumab deruxtecan do not exist in the public domain.

What to watch next

Two Phase 3 breast cancer trials are fully enrolled. TQB2102-III-01 (NCT06561607) tests TQB2102 against investigator-choice chemotherapy in HER2-low recurrent or metastatic disease in about 542 patients, with enrolment completed in February 2026. TQB2102-III-02 tests it against T-DM1 in HER2-positive advanced disease, with full enrolment announced on 30 March 2026. The drug also carries three China CDE breakthrough therapy designations, the most recent granted in August 2026 for chemo-naive unresectable or metastatic HER2-low breast cancer.

Markets are treating the deal as a pipeline option rather than an earnings event. Cipla shares closed 0.89% lower at ₹1,410.80 on the NSE on 31 August 2026 and were about 0.8% higher in early trade the next day at around ₹1,420.9. Value only crystallises if the Chinese Phase 3 data hold up, regulators in India and South Africa accept a workable evidence package, and Cipla prices the product inside local oncology budgets while CTTQ supplies it without interruption.

Source: Cipla press release and Sino Biopharm HKEX announcements, 31 August 2026.